{
 "name": "國鼎",
 "slug": "tw-4132",
 "aliases": [
  "國鼎生物科技股份有限公司",
  "Golden Biotechnology Corporation",
  "4132"
 ],
 "ticker": "4132",
 "industry": "生技醫療業",
 "website": "https://www.goldenbiotech.com",
 "summary": "",
 "facts": [
  {
   "claim": "管線：Antroquinonol（Hocena）",
   "value": "轉移性胰臟癌第一線（合併標準療法）｜得進行第三期試驗，擬申請IRB｜美國",
   "unit": "",
   "as_of": "2026-02-09",
   "source": "https://www.goldenbiotech.com/zh-tw/news.php?act=view&id=97",
   "note": "發言日期115/02/09；主旨：公告本公司得進行研發中小分子新藥Antroquinonol(Hocena)第三期人體臨床試驗。公司稱IND提出39日未接獲FDA通知；不可解讀為三期已開始收案。"
  },
  {
   "claim": "管線：Antroquinonol（Hocena）",
   "value": "慢性B型肝炎｜第二期試驗已完成（歷史試驗）｜台灣",
   "unit": "",
   "as_of": "2026-10-19",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT03625102",
   "note": "NCT03625102；COMPLETED為此登錄試驗狀態，不代表藥物已核准、全部研發結束或目前所有地區階段。"
  },
  {
   "claim": "管線：Antroquinonol（Hocena）",
   "value": "異位性皮膚炎｜第二期試驗已完成（歷史試驗）｜台灣",
   "unit": "",
   "as_of": "2019-08-29",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT03622463",
   "note": "NCT03622463；COMPLETED為此登錄試驗狀態，不代表藥物已核准、全部研發結束或目前所有地區階段。"
  },
  {
   "claim": "管線：Antroquinonol（Hocena）",
   "value": "高膽固醇血症與高血脂症｜第二期試驗已完成（歷史試驗）｜台灣",
   "unit": "",
   "as_of": "2020-01-02",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT02719028",
   "note": "NCT02719028；COMPLETED為此登錄試驗狀態，不代表藥物已核准、全部研發結束或目前所有地區階段。"
  },
  {
   "claim": "管線：Antroquinonol（Hocena）",
   "value": "非小細胞肺癌｜第二期試驗已完成（歷史試驗）｜台灣、美國",
   "unit": "",
   "as_of": "2019-12-26",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT02047344",
   "note": "NCT02047344；COMPLETED為此登錄試驗狀態，不代表藥物已核准、全部研發結束或目前所有地區階段。"
  },
  {
   "claim": "管線：Antroquinonol（Hocena）",
   "value": "輕中度COVID-19住院患者｜第二期試驗已完成（歷史試驗）｜阿根廷、秘魯、美國",
   "unit": "",
   "as_of": "2023-12-13",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT04523181",
   "note": "NCT04523181；COMPLETED為此登錄試驗狀態，不代表藥物已核准、全部研發結束或目前所有地區階段。"
  },
  {
   "claim": "管線：Antroquinonol（Hocena）",
   "value": "急性骨髓性白血病｜第二期試驗已完成（歷史試驗）｜Russia",
   "unit": "",
   "as_of": "2021-02-03",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT03823352",
   "note": "NCT03823352；COMPLETED為此登錄試驗狀態，不代表藥物已核准、全部研發結束或目前所有地區階段。"
  },
  {
   "claim": "授權合作：Antroquinonol",
   "value": "BNC Korea Co., Ltd.｜南韓、巴西、土耳其、印尼｜2021-01-04",
   "unit": "",
   "as_of": "2022-11-22",
   "source": "https://www.goldenbiotech.com/zh-tw/news.php?act=view&id=29",
   "note": "COVID-19授權；日期為公告明列之前次開發合作及授權合約簽署日。2022-11-22公告Definitive Licensing Agreement，未另揭露其實際簽署日；本筆金額取自該次更新。"
  },
  {
   "claim": "簽約金：Antroquinonol",
   "value": 4000000,
   "unit": "美元",
   "as_of": "2022-11-22",
   "source": "https://www.goldenbiotech.com/zh-tw/news.php?act=view&id=29",
   "note": "簽約里程金；包含在1500萬美元合計授權里程金內。"
  },
  {
   "claim": "里程碑金上限：Antroquinonol",
   "value": 11000000,
   "unit": "美元",
   "as_of": "2022-11-22",
   "source": "https://www.goldenbiotech.com/zh-tw/news.php?act=view&id=29",
   "note": "執行COVID-19第三期臨床及取得NDA之後續里程金，不含400萬美元簽約金。"
  },
  {
   "claim": "已收金額（公告日為準）：Antroquinonol",
   "value": 4000000,
   "unit": "美元",
   "as_of": "2022-11-22",
   "source": "https://www.goldenbiotech.com/zh-tw/news.php?act=view&id=29",
   "note": "公告稱於2021-01-08及2021-02-26合計已收到400萬美元；非1500萬美元全數已收。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-4132.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}